Schwendel-Van Deusen is pleased to announce that EpiVax, a Providence, Rhode Island-based bioanalytical CRO focused on immunogenicity risk assessment for pharmaceutical and biotechnology companies, has been acquired by SV Health Investors. Schwendel-Van Deusen served as M&A advisor to EpiVax on the transaction. The acquisition was publicly announced on April 2, 2026.

​

EpiVax represents a highly differentiated healthcare services platform at the intersection of scientific expertise, predictive analytics, and mission-critical outsourced support for pharmaceutical and biotechnology companies. With more than 25 years of operating history, a strong scientific reputation, and a specialized position in immunogenicity risk assessment, the company has established itself as a trusted partner to life sciences clients seeking to identify and mitigate development risk earlier in the drug development process. The transaction highlights continued buyer interest in specialized, technology-enabled healthcare services businesses with strong intellectual differentiation and clear opportunities for continued expansion.

​

Headquartered in Providence, Rhode Island, EpiVax is a bioanalytical CRO focused on immunogenicity risk assessment for pharmaceutical and biotechnology companies. Founded in 1998, the company has built a strong position in pre-clinical drug development through its predictive analytical software platform, ISPRI, and its in vitro laboratory services.

The acquisition represents a new platform investment for SV Health Investors and builds on the firm’s experience in outsourced pharma services. According to the company’s announcement, EpiVax is expected to continue expanding its capabilities following the transaction, including advanced computational tools, cell-based assay applications, and broader analytical consulting services.

​

“This transaction marks an important milestone for EpiVax and reflects the strength of the company we have built over more than 25 years,” said Rich-Henry Schabowsky, PhD, JD, CEO of EpiVax. “We believe SV Health Investors is the right partner to support our next phase of growth as we continue expanding our scientific capabilities, computational tools, and service offerings for pharmaceutical and biotechnology clients. Schwendel-Van Deusen understood how to position EpiVax’s unique platform and helped us identify a partner aligned with our long-term vision.”

​

“EpiVax has built a differentiated business at the intersection of scientific expertise, computational capability, and mission-critical outsourced services for the biopharma industry,” said Paul Schwendel, Founder and Managing Partner at Schwendel-Van Deusen. “We were proud to advise EpiVax on this transaction and believe SV Health Investors is well positioned to support the company in its next phase of growth.”

​

This transaction further reflects Schwendel-Van Deusen’s focus on advising founder-led, innovative, and strategically valuable businesses. SVD continues to work with clients on mergers and acquisitions, capital raises, and other strategic transactions where specialized market positioning and thoughtful process execution are critical to achieving a successful outcome.

​

About EpiVax

Founded in 1998, EpiVax is a bioanalytical CRO specializing in immunogenicity risk assessment for the pharmaceutical and biotechnology industries. EpiVax’s predictive analytical software platform, ISPRI, and in vitro laboratory services help life sciences companies identify safety and efficacy risks early in drug development, reduce timelines and R&D costs, and support more efficient regulatory-ready strategies.

​

About SV Health Investors

SV Health Investors is a private investment firm focused on the healthcare and life sciences sector. Founded in 1993, the firm has offices in Boston and London and invests across multiple healthcare-focused strategies, including growth-buyout investments in pharma services, medical technology, and tech-enabled healthcare services.

​

About Schwendel-Van Deusen

Schwendel-Van Deusen is a global boutique investment bank focused on advising clients on strategic and transformative transactions. The firm provides M&A advisory, debt and equity capital advisory, and other strategic financial advisory services to businesses navigating complex growth, ownership, and transaction opportunities.

​

Contacts
Paul Schwendel - Founder and Managing Partner

(paul@schwendel-vandeusen.com)

Brandon Schwendel - COO

(brandon@schwendel-vandeusen.com)